A health system can spend 12+ months evaluating an AI product before enterprise deployment.

UCSF Health says a full evaluation can span clinical, technical, financial and compliance reviews, IT integration and staff workflow planning, and that even promising tools can remain confined to a handful of settings rather than scaling across the enterprise.

Now compare that with Kaiser Permanente.

After a 10-week ambient-AI pilot in early 2024, Kaiser deployed the technology across its eight regions, 40 hospitals and more than 600 medical offices. Its subsequent work has included quality assurance and an organization-wide responsible-AI framework.

That is the commercialization gap I wanted to map.

The useful question is no longer:

“Which hospitals are interested in AI?”

Almost every sophisticated health system is interested.

The better question is:

Which health systems have the buyer ownership, evidence processes, integration capability and scale pathways required to turn AI into a real enterprise contract?

A pilot is not the commercial outcome

For founders, “we have a pilot with a major hospital” sounds like traction.

For investors, it should trigger another five questions:

Who owns the KPI?

Who controls the budget?

What evidence unlocks rollout?

What integration survives beyond the pilot?

What happens after site #1?

That distinction matters because the commercial sequence is:

INTEREST → EVALUATION → PILOT → PAID ROLLOUT → MULTI-SITE → RENEWAL → EXPANSION

A startup can succeed at the first three and still fail commercially.

My six-gate Health AI buyer framework

The visual uses five core commercial dimensions. For actual enterprise selling, I would add a sixth.

BUYER → EVIDENCE → ROI → INTEGRATION → GOVERNANCE → SCALE

Each solves a different hospital objection.

A startup scoring highly on five and poorly on one can still get stuck.

1. Kaiser Permanente: what real scale looks like

Kaiser is useful because it demonstrates the difference between experimentation and deployment.

Its ambient-AI program moved from pilot into all eight Kaiser regions, 40 hospitals and 600+ medical offices. Kaiser also describes a responsible-AI framework focused on patient safety and clinical impact, applied not just to ambient documentation but also EHR generative-AI capabilities, imaging and other tools.

That tells founders something important.

Kaiser did not simply buy:

“an AI scribe.”

It needed:

clinical usability

accuracy

quality assurance

workflow compatibility

governance

and ultimately:

enterprise-scale repeatability.

Founder lesson

If you approach a sophisticated integrated system, sell the deployment system, not only the model.

The product story should answer:

“Why does site #20 become easier than site #1?”

2. Cedars-Sinai: integration + governance are becoming inseparable

Cedars-Sinai is another strong signal.

In May 2026, it gave clinicians enterprise access to OpenEvidence, linking medical evidence with relevant patient information from the EHR. Cedars also plans to incorporate its own pathways, protocols and best practices into the platform.

But the commercial signal is bigger than the vendor choice.

Cedars says AI systems undergo review by a designated committee before going live. That committee includes data scientists, clinical experts, administrative leaders and other relevant specialists, and deployed tools can be audited for impact.

Cedars explicitly says it wants a:

coherent, secure AI ecosystem

rather than isolated pilots.

Founder lesson

A standalone AI feature increasingly competes against the hospital's enterprise architecture strategy.

The stronger pitch is:

“Here is where we fit into your AI ecosystem.”

Not:

“Here is another clever model.”

3. UCSF Health: build with the buyer rather than around the buyer

UCSF's 2026 Converge initiative may be one of the most interesting market-access signals on the West Coast.

UCSF Health, Kleiner Perkins and Doerr Capital created the program to bring a small number of AI companies directly into the health system to co-develop with clinicians, operators and technology leaders. Projects are intended to address real care-delivery needs while accounting for workflow, technology, governance and evaluation from the start.

That attacks one of the biggest HealthTech failure modes:

building a technically impressive product outside the environment where it eventually needs to operate.

UCSF explicitly notes that companies can spend substantial time and capital building products that later prove difficult to integrate, adopt or align with hospital workflows.

Founder lesson

For difficult clinical categories, co-development can be a commercialization strategy.

It can create:

local evidence

workflow proof

integration proof

reference credibility

and:

enterprise-learning assets.

4. UCLA Health: evidence is becoming part of market access

UCLA launched its Innovations and Outcomes Validation of AI, or INOVAi, Center in June 2026.

Its mandate spans AI's full implementation lifecycle, including:

usability

feasibility

workflow testing

prospective clinical trials

and:

pragmatic implementation studies.

UCLA frames the problem clearly: knowing whether an AI tool is safe, effective and useful in real-world clinical practice remains a major gap.

Founder lesson

For clinical AI, evidence is not something you finish before GTM.

Evidence is part of GTM.

A founder should therefore map:

Evidence needed to get the pilot

→ evidence needed to expand

→ evidence needed to renew

as three different milestones.

5. Sutter Health: enterprise AI is moving beyond individual tools

Sutter gives us two particularly useful 2026 signals.

First, it describes systemwide use of Aidoc's enterprise clinical-AI platform and projects that the technology will analyze roughly 740,000 patient images in 2026 and flag around 17,000 cases for potential acute needs.

Second, Sutter joined 11 other health systems in the Diagnostic AI Consortium, collectively caring for nearly 20 million patients annually. The consortium is explicitly focused on developing diagnostic workflows, measuring safety and impact, and creating shared implementation and governance practices.

Sutter also integrated OpenEvidence into Epic workflows in 2026.

Founder lesson

The buyer is increasingly asking:

“Can this work as enterprise infrastructure?”

not simply:

“Does the algorithm work?”

6. Stanford Health Care: the evaluation machinery itself is sophisticated

Stanford is a good example of why a lower short-term buying signal does not mean a weak innovation environment.

Its Responsible AI Life Cycle evaluates proposed AI applications across areas including ethics, usefulness, performance and deployment. Stanford's FURM framework specifically includes financial projections, IT feasibility, deployment strategy and prospective monitoring.

Stanford also uses ambient AI in clinical care and published 2026 ED data showing that, when used, ambient AI was associated with 28% lower median on-shift documentation time and 16% lower total EHR time in the analyzed encounters. Adoption, however, was uneven, which itself is an important implementation lesson.

Founder lesson

Do not mistake:

clinical performance

for:

organizational usefulness.

Stanford's framework asks whether the workflow is:

fair

useful

reliable

financially sustainable

and:

operationally deployable.

That is closer to what enterprise diligence actually looks like.

7. Providence: real-world ROI needs scale data

Providence published a large real-world evaluation of ambient AI in May 2026.

The study included 1,547 active physicians and advanced-practice providers, analyzing EHR metadata rather than relying only on satisfaction surveys. Researchers found statistically significant reductions in documentation time during clinic hours and sustained decreases in after-hours documentation, while emphasizing that individual improvements were modest.

That qualification matters.

A product does not necessarily need a spectacular per-clinician effect if a smaller improvement can be multiplied across thousands of clinicians.

Founder lesson

Your ROI model should include:

VALUE PER USER × NUMBER OF USERS × FREQUENCY OF USE

Not just:

“Doctors like it.”

8. UW Medicine: governance can itself determine market access

UW Medicine's AI policy makes the internal review threshold explicit.

Proposed uses can require internal review when AI is patient-facing, affects EHR documentation, uses clinical data or PHI, affects clinical care, or automates coding and billing.

UW Medicine also publicly describes AI being integrated into radiology workflows for imaging prioritization and clinical pilots of AI transcription.

Founder lesson

If your startup cannot answer:

What data enters?

What output leaves?

Who validates it?

What happens when it is wrong?

How is usage monitored?

then your commercial problem may appear before procurement even starts.

So who is “actually buying”?

I would treat the heatmap as a public-signal intelligence layer, not an official procurement ranking.

My current editorial interpretation is:

Strong / Active / Watch does not mean an open RFP, available budget or current vendor search.

It means the public evidence provides different levels of signal around evaluation, deployment and scaling capacity.

Category matters more than most founder lists acknowledge

A hospital does not buy all AI through the same motion.

Your market map includes four distinct commercial categories.

Ambient / documentation

Abridge, Ambience Healthcare, Nabla, Suki, DeepScribe, Commure

The pain is obvious:

documentation time

after-hours work

cognitive load

patient interaction

and:

clinician burnout.

Kaiser's scale demonstrates the category can move enterprise-wide. Stanford and Providence provide additional real-world evidence that documentation time can improve, although adoption patterns and magnitude of benefit still matter.

The challenge is competition.

So ambient vendors increasingly need to differentiate on:

specialty workflow

note quality

coding / downstream workflows

integration

enterprise governance

and:

multi-role expansion.

Likely buyer ownership

CMIO
physician operations
clinical informatics
CIO / digital
service-line leadership

Workflow / operations

Qventus, Notable, Hyro, LeanTaaS, Laudio, Regard

This is where ROI can become extremely concrete.

Possible KPIs include:

length of stay

discharge volume

bed capacity

OR utilization

referral conversion

appointment access

administrative workload

and:

staff productivity.

Qventus, for example, markets its inpatient-capacity platform around measurable excess-day reduction, capacity and ROI; its published customer material includes multi-million-dollar savings examples. These are vendor-reported results, so they should be validated independently when used in diligence.

Notable similarly reports reductions in referral turnaround and other access metrics from deployments; again, these are company-reported commercial case studies rather than independent benchmarks.

Why I like the category commercially

The buyer usually owns an operational KPI.

That gives founders a clean equation:

CAPACITY CREATED × ECONOMIC VALUE OF CAPACITY

RCM / revenue AI

AKASA, CodaMetrix, SmarterDx, Nym, Plenful, Adonis

The strongest advantage here is buyer clarity.

The executive owner is often:

CFO

chief revenue-cycle officer

coding leadership

or:

finance operations.

The economic outcome can also be measured relatively quickly:

coding cost

denials

revenue capture

turnaround time

A/R

staff requirement

and:

margin.

CodaMetrix currently markets a 5:1 five-year ROI and up to 30% lower coding cost from its platform. These are vendor-reported figures, not an industry-wide benchmark, but they demonstrate how explicitly financial the category's sales story can be.

That is one reason my commercial lens puts RCM among the more straightforward categories for building a CFO-grade value proposition.

Clinical / imaging AI

Aidoc, Viz.ai, RapidAI, Rad AI, Cleerly, Heartflow

This category is different.

Clinical AI can be highly valuable, but its sales motion often has to survive:

clinical validation

regulatory scrutiny

workflow impact

false-positive / false-negative analysis

bias assessment

governance

integration

and:

post-deployment monitoring.

The FDA continues to maintain and update its list of authorized AI-enabled medical devices, with radiology strongly represented among recent 2026 authorizations.

That makes this category less suited to a generic:

“AI saves time.”

pitch.

Stronger commercial equation

CLINICAL IMPACT + WORKFLOW IMPACT + ECONOMIC IMPACT − IMPLEMENTATION / GOVERNANCE BURDEN

My commercial category read

I would frame it this way:

RCM AI

Best when: financial ROI is immediate and attributable.

Workflow AI

Best when: capacity, throughput or operational friction is measurable.

Ambient AI

Best when: adoption is broad enough for small per-user benefits to compound at enterprise scale.

Clinical AI

Best when: the clinical outcome is meaningful enough to justify the higher evidence and governance burden.

That is a commercial framework, not a universal “fastest category” ranking.

The calculation founders should run before pursuing a 12-month health-system sale

Here is where the free calculator becomes useful.

Suppose your enterprise GTM team burns:

$100K/month

and the buyer evaluation takes:

12 months.

Commercial burn exposure:

$100K × 12 = $1.2M

Now add:

$150K

for pilot engineering, implementation and support.

Total capital exposed before rollout:

$1.35M

Now compare that with contract economics

Assume:

$500K first-year ACV

35% pilot-to-paid probability

and:

70% gross margin.

Probability-weighted ACV:

$500K × 35% = $175K

Probability-weighted gross profit:

$175K × 70% = $122.5K

This is deliberately simplified.

It is not a valuation or probability forecast.

But it exposes the underlying commercial problem:

A famous logo can be an extremely expensive low-probability sales opportunity.

The ROI of buyer intelligence is therefore partly avoided waste

Suppose your team starts with:

25 health systems.

Research shows only:

32%

match your:

category

buyer problem

evidence maturity

integration profile

and:

commercial timing.

That produces:

8 high-fit accounts

rather than 25.

If only three already have meaningful senior-level relationship coverage, the immediate BD problem becomes very specific:

build qualified access to the remaining five.

That is much more useful than generating another:

“Top 500 U.S. hospitals” spreadsheet.

Founders should model an evaluation kill-switch

Because AI review can run for a year or more, I would not allow enterprise opportunities to remain indefinitely in “promising conversations.”

Set stage gates.

Day 30

Is there a named problem owner?

Day 60

Is there an agreed evidence requirement?

Day 90

Is integration feasibility confirmed?

Before pilot

Is there a paid-rollout hypothesis?

Mid-pilot

Are decision KPIs being measured?

End of pilot

Is there an actual procurement decision date?

If the answers remain vague, continuing the pursuit should require explicit justification.

The pilot contract should already contain the scale thesis

A weak pilot asks:

“Does the product work?”

A stronger enterprise pilot asks:

“What must be true for this health system to buy and expand it?”

Define before launch:

success metrics

economic KPI

clinical KPI

workflow KPI

technical acceptance

governance threshold

rollout decision-maker

paid-rollout trigger

and:

next-site candidate.

That is how pilot-to-revenue becomes designed rather than hoped for.

Investor diligence should move beyond pilot count

If a startup tells me:

“We have eight hospital pilots.”

I would ask:

How many are paid?

How many converted?

How many expanded?

How many renewed?

How many deployed across multiple sites?

How long did each stage take?

How much implementation work was required?

The better progression is:

PILOT → PAID → MULTI-SITE → RENEWAL → EXPANSION

That sequence tells an investor much more about defensibility than the number of logos on the pitch deck.

The six numbers I would put in every Health AI board deck

For enterprise HealthTech, I would track:

1. Median days to pilot
2. Median days pilot → paid
3. Pilot-to-paid conversion
4. Paid-to-multi-site conversion
5. Implementation cost as % of ACV
6. Net expansion after 12 months

Those metrics reveal whether the product is becoming:

easier to buy

easier to deploy

and:

easier to expand.

That is commercial maturity.

The Market Intelligence Layer

This is the layer I think founders often skip.

They understand:

their product

and:

the hospital market.

But they have not mapped:

which hospitals already have governance infrastructure

which are running enterprise programs

which category each system is prioritizing

which executive owns the KPI

what evidence they expect

which EHR / integration constraints matter

where a pilot could plausibly scale

and:

when the buying window is realistic.

So my framework becomes:

BUYER × EVIDENCE × ROI × INTEGRATION × GOVERNANCE × SCALE

That is the intelligence layer between:

“This hospital uses AI”

and:

“This hospital has a credible reason to buy this company.”

Where I can help

This is also where the HealthTech Buyer Pipeline Sprint fits.

The objective is not to send a founder another generic list of health systems.

I map:

25 priority healthcare buyers / strategic accounts

plus:

15 relevant decision-makers

around the company's actual:

AI category

use case

evidence burden

buyer KPI

integration path

public adoption signals

and:

commercial timing.

Then the next question becomes:

Which five to eight accounts deserve the next six months of enterprise BD?

rather than:

“Which 500 hospitals can we email?”

HealthTech Buyer Pipeline Sprint: 25 Buyers + 15 Decision-Makers

Final takeaway

The headline is not really:

“AI evaluation takes 12 months.”

It is:

12 MONTHS IS ONLY WORTH IT WHEN THE BUYER CAN SCALE THE RESULT.

The most attractive health-system opportunity is therefore not always the largest hospital or most prestigious logo.

It is the buyer where:

OWNER + EVIDENCE + ROI + INTEGRATION + GOVERNANCE + SCALE

line up strongly enough to justify the cost of the sales cycle.

For founders, that protects runway.

For hospital executives, it creates more defensible AI procurement.

For investors, it separates:

pilot activity

from:

commercial infrastructure.

And that is the difference between an impressive AI demo and repeatable healthcare revenue.